Picard Medical (NYSE: PMI) launches Cruxx to MedTech podcast series

Rhea-AI Filing Summary

Picard Medical, Inc. filed a current report describing a new communications initiative. The company issued a press release announcing the launch of the Cruxx to MedTech Podcast, a series that will explore the SynCardia Total Artificial Heart and the Emperor device. The press release is included as Exhibit 99.1 and is incorporated by reference. The company specifies that the information in this report and its exhibits is being furnished, not filed, so it is not subject to certain Exchange Act liability provisions or automatically incorporated into other securities filings.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0002030617 0002030617 2026-01-13 2026-01-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 13, 2026

Picard Medical, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-42801		86-3212894
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1992 E Silverlake
Tucson AZ, 85713

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (520) 545-1234

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		PMI		The NYSE American, LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On January 13, 2026, Picard Medical, Inc. issued a press release announcing the launch of the Cruxx to MedTech Podcast, a series exploring the SynCardia Total Artificial Heart and the Emperor device. A copy of the press release is furnished as Exhibit 99.1 and incorporated by reference herein.

The information in this report and the exhibits attached hereto shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are being filed herewith:

Exhibit No.		Description
99.1		Press Release, dated January 13, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Picard Medical, Inc.
	By:	/s/ Patrick NJ Schnegelsberg
		Name:	Patrick NJ Schnegelsberg
		Title:	Chief Executive Officer

Dated: January 13, 2026

2

FAQ

What did Picard Medical (PMI) report in this 8-K filing?

Picard Medical reported that it issued a press release announcing the launch of the Cruxx to MedTech Podcast, focused on its SynCardia Total Artificial Heart and Emperor device.

What is the focus of Picard Medical's Cruxx to MedTech Podcast?

The Cruxx to MedTech Podcast is described as a series exploring the SynCardia Total Artificial Heart and the Emperor device.

How did Picard Medical disclose the podcast launch to investors?

Picard Medical disclosed the podcast launch through a press release dated January 13, 2026, which is furnished as Exhibit 99.1 to the report.

Is the information about the Cruxx to MedTech Podcast considered "filed" with the SEC?

No. The company states that the information in the report and its exhibits is furnished, not filed, and is not subject to the liabilities of Section 18 of the Exchange Act.

Which Picard Medical securities are listed on an exchange?

The filing notes that Picard Medical’s common stock, par value $0.0001 per share, trades on the NYSE American under the symbol PMI.

Where can investors find the full details of Picard Medical's podcast announcement?

Full details are in Exhibit 99.1, the press release dated January 13, 2026, which is attached to the report.